Publication | Closed Access

Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia

MedicineCell AdhesionFniii14 PeptidePeptide TherapeuticCell-matrix InteractionCombination TherapyAnti-cancer AgentMatrix BiologyRadiation OncologyOncologyCell BiologyAnticancer DrugTumor MicroenvironmentCancer Research